Sunita Somvanshi
The US Food and Drug Administration approved a new cancer treatment on August 26 that showed survival improvement in clinical testing, offering hope to patients facing one of medicine’s most difficult diagnoses. The drug, called Rasonque (generic name: daraxonrasib), is a RAS inhibitor designed to target RAS-driven cancer signaling in pancreatic cancer.
Here’s what makes this significant. Pancreatic cancer kills quickly. In the clinical trial, patients taking Rasonque achieved a median overall survival of 13.2 months compared to 6.7 months in the standard-chemotherapy group. The median survival was nearly twice as long.
The trial enrolled 500 patients with advanced pancreatic cancer who had already received at least one prior treatment or couldn’t tolerate intensive chemotherapy. Half received Rasonque as a daily tablet. Half received investigator’s choice standard chemotherapy. After following these patients over time, researchers found that 53.3 percent of Rasonque patients were alive at 12 months, compared to 18.7 percent of those on standard chemotherapy.
The FDA approved the application about 6.5 months ahead of its goal date under its expedited review processes, including the Commissioner’s National Priority Review Voucher pilot program.
Daraxonrasib works by inhibiting RAS signaling molecules that drive cancer cell division. RAS mutations appear in roughly one-third of all human cancers, but oncologists have struggled for decades to develop drugs that effectively target RAS. The technical barriers are substantial. RAS proteins sit inside cells and are notoriously difficult for drugs to reach and inhibit. The approval represents a new clinical application of RAS-targeted therapy in pancreatic cancer.
The drug isn’t a cure. That needs to be stated clearly. It extends survival in advanced metastatic pancreatic cancer for the defined patient population studied in the trial.
Side effects accompany the benefit. The FDA’s safety data showed that 43.6 percent of patients on Rasonque experienced grade 3 or higher adverse reactions—serious side effects. Common adverse effects included rash, diarrhea, mouth sores, nausea, fatigue, vomiting, abdominal pain, swelling, decreased appetite, and bleeding. Grade 3 or higher adverse reactions were reported less frequently in the daraxonrasib group than in the standard-treatment group.
The approval carries important limitations. Rasonque is approved specifically for adults with advanced metastatic pancreatic adenocarcinoma who have progressed after at least one prior treatment. It’s not approved for early-stage pancreatic cancer. It’s not approved as a first-line treatment. The FDA approves drugs for defined patient populations based on trial data, not for all patients with a disease.
Clinical trials are ongoing in other pancreatic cancer settings. Studies registered on ClinicalTrials.gov show tests of daraxonrasib in first-line metastatic disease (treatment-naive patients) and resected pancreatic cancer (patients after surgery). Those trials will determine whether Rasonque has a role in earlier disease stages or as initial therapy.
For patients currently facing advanced pancreatic cancer diagnosis after prior treatment, Rasonque represents a treatment option where few existed before.
